Microbot Medical Preps Full Market Release of LIBERTY System
Event summary
- Microbot Medical to present at Roth Conference on March 23, 2026, with CEO Harel Gadot leading a fireside Q&A.
- Company plans full market release of LIBERTY system at SIR conference in April 2026.
- Limited market release shows multi-site traction and procedural diversity.
- LIBERTY is the only FDA-cleared single-use robotic system for peripheral endovascular procedures.
The big picture
Microbot Medical's strategic push aligns with the broader trend of robotic-assisted minimally invasive procedures, aiming to reduce physician strain and improve procedural precision. The full market release of LIBERTY could position the company as a key player in endovascular robotics, though it faces competition from established medical device firms and emerging startups. The Roth Conference appearance underscores the company's focus on growth-oriented investor engagement amid a competitive healthcare technology landscape.
What we're watching
- Commercial Momentum
- Whether the limited market release traction will translate into sustained adoption post-full launch.
- Regulatory Dynamics
- How FDA clearance and future regulatory pathways may impact commercialization timelines.
- Competitive Positioning
- The pace at which Microbot can differentiate LIBERTY in a growing robotic endovascular market.
Related topics